Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study

被引：6

作者：

Sugimoto, Takeya ^{[1
]}

Fujimoto, Daichi ^{[1
,2
]}

Sato, Yuki ^{[2
]}

Tamiya, Motohiro ^{[3
]}

Yokoi, Takashi ^{[4
]}

Tamiya, Akihiro ^{[5
]}

Iwasawa, Shunichiro ^{[6
]}

Hata, Akito ^{[7
]}

Uchida, Junji ^{[8
]}

Fukuda, Yasushi ^{[9
]}

Hara, Satoshi ^{[10
]}

Kanazu, Masaki ^{[11
]}

Hirano, Katsuya ^{[12
]}

Kokubo, Masaki ^{[13
]}

Yamamoto, Nobuyuki ^{[1
]}

机构：

[1] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, Wakayama, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[3] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[4] Hyogo Coll Med, Dept Thorac Oncol, Nishinomiya, Hyogo, Japan

[5] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Internal Med, Sakai, Osaka, Japan

[6] Chiba Univ, Dept Respirol, Grad Sch Med, Chiba, Japan

[7] Kobe Minimally Invas Canc Ctr, Div Thorac Oncol, Kobe, Hyogo, Japan

[8] Osaka Gen Med Ctr, Dept Resp Med, Osaka, Japan

[9] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[10] Itami City Hosp, Dept Resp Med, Itami, Hyogo, Japan

[11] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[12] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan

[13] Kobe City Med Ctr Gen Hosp, Dept Radiat Oncol, Kobe, Hyogo, Japan

来源：

INVESTIGATIONAL NEW DRUGS | 2021年 / 39卷 / 03期

关键词：

Durvalumab; Non-small cell lung cancer; Radiation pneumonitis; Immune checkpoint inhibitors; Chemoradiotherapy; PHASE-III; THORACIC RADIOTHERAPY; DOCETAXEL; CHEMOTHERAPY; CISPLATIN; NIVOLUMAB; TRIAL;

D O I：

10.1007/s10637-020-01060-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction/Background Durvalumab demonstrated a good efficacy and safety in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in the PACIFIC trial. Although a history of radiation pneumonitis (RP) has been reported to increase the risk of pneumonitis associated with programmed death-1 inhibitors, the safety and efficacy of durvalumab in patients with baseline Grade 1 RP have not been assessed. Therefore, we carried out a multicenter prospective cohort study to evaluate the efficacy and safety of durvalumab in these patients. Patients and Methods This was a multicenter prospective cohort study of 35 patients with Grade 1 RP after CCRT and before durvalumab initiation. This study was a first prespecified analysis for the first 20 patients with the primary objective of assessing the short-term safety; it was assessed 3 months after durvalumab initiation. Results Twenty patients were enrolled in this study between March 1, 2019, and September 3, 2019. Three patients (15%) experienced drug-related Grade >= 3 adverse events, while three patients (15%) had Grade >= 2 pneumonitis/RP within 3 months after durvalumab initiation. Three months after durvalumab initiation, all the patients were alive and four patients (20%) experienced disease progression. Conclusion Durvalumab can be a feasible treatment option for patients with stage III NSCLC with baseline Grade 1 RP following CCRT.

引用

页码：853 / 859

页数：7

共 18 条

[1]

[Anonymous], 2020, ASTRAZENECA MEDICHAN

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[6] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[7] Radiation-Induced Lung Injury Assessment and Management [J].

Hanania, Alexander N. ;

Mainwaring, Walker ;

Ghebre, Yohannes T. ;

Hanania, Nicola A. ;

Ludwig, Michelle .

CHEST, 2019, 156 (01) :150-162

[8] Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study [J].

Horinouchi, Hidehito ;

Atagi, Shinji ;

Oizumi, Satoshi ;

Ohashi, Kadoaki ;

Kato, Tomohiro ;

Kozuki, Toshiyuki ;

Seike, Masahiro ;

Sone, Takashi ;

Sobue, Tomotaka ;

Tokito, Takaaki ;

Harada, Hideyuki ;

Maeda, Tadashi ;

Mio, Tadashi ;

Shirosaka, Ikue ;

Hattori, Kana ;

Shin, Eisei ;

Murakami, Haruyasu .

CANCER MEDICINE, 2020, 9 (18) :6597-6608

[9] Cancer treatment and survivorship statistics, 2019 [J].

Miller, Kimberly D. ;

Nogueira, Leticia ;

Mariotto, Angela B. ;

Rowland, Julia H. ;

Yabroff, K. Robin ;

Alfano, Catherine M. ;

Jemal, Ahmedin ;

Kramer, Joan L. ;

Siegel, Rebecca L. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) :363-385

[10] Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer A National Cancer Database Survey [J].

Morgensztern, Daniel ;

Ng, Shean Huey ;

Gao, Feng ;

Govindan, Ramaswamy .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) :29-33

← 1 2 →